MARKET

XBIT

XBIT

XBiotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.04
-0.48
-3.09%
After Hours: 15.04 0 0.00% 16:45 08/07 EDT
OPEN
15.78
PREV CLOSE
15.52
HIGH
15.78
LOW
15.00
VOLUME
104.81K
TURNOVER
--
52 WEEK HIGH
26.40
52 WEEK LOW
6.95
MARKET CAP
433.95M
P/E (TTM)
1.600
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average XBIT stock price target is 18.00 with a high estimate of 18.00 and a low estimate of 18.00.

EPS

XBIT News

More
XBiotech: Well Funded, Working On The Next Bermekimab, And Undervalued
Seeking Alpha · 07/31 04:00
Top Small Cap Stocks for August 2020
Investopedia · 07/29 19:32
Grifols delivers first batch of hyperimmune globulin for COVID-19 studies
Seeking Alpha · 07/28 15:22
XBiotech Breakthrough, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha · 07/25 10:30
XBiotech in the green on advancement of new anti-inflammatory antibody
Thinly traded micro cap XBiotech (XBIT +1.4%) is up modestly out of the gate this morning in reaction to its announcement that its R&D team has engineered
seekingalpha · 07/22 18:32
XBiotech Reports Achievement Of Milestone In Development Of Inflammation-Fighting True Human Antibodies: Co. Permitted To Pursue Discovery Of New True Human Anti-IL-i⍺ Antibodies for Use In All Areas Of Medicine Except Dermatology
Benzinga · 07/22 13:22
XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ Therapy
After Sale of its Previous Anti-IL-1a True Human Antibody, Company Now Has Production Cell to Manufacture New Molecule for Launch of Clinical Studies in 2021AUSTIN, Texas, July 22, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it has ac
GlobeNewswire · 07/22 13:20
XBiotech antibody shows potential for treating stroke-related brain injury
XBiotech (XBIT +2.6%) announces encouraging results from research conducted in Switzerland that supports the rationale of interleukin-1 alpha (IL-1⍺) block
seekingalpha · 07/14 19:32

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About XBIT

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).
More

Webull offers kinds of XBiotech Inc stock information, including NASDAQ:XBIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XBIT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XBIT stock methods without spending real money on the virtual paper trading platform.